$39 for q3 - not bad, considering, page-13

Yes I am in strong agreement with Mita, so I am going to reinforce this post with my thoughts. While it is hard to say what "good" is when sales are falling, if we can sustain a figure of only 6% fall year on year in sales for many years to come we will have done very well and the company will be able to self fund its new products, even at the extremely modest pace they are going at. There are many potential threats to sales, not just generics/other competitors. How about a nasty warning on the product from the FDA? Or what about the fact that using the product in its primary "off label" use has been shown not to be terribly effective?

No, a roughly 6% fall is a "good" result and every year it only drops by that should be regarded as bonus and as a holder I will be glad about it. I fear greater falls. All drugs have a lifecycle - its part of the territory. Got to accept that all drugs eventually get dropped for more effective ones.